Partial vena cava occlusion (VCO) to counteract refractory heart failure: A new era in interventional heart failure strategy. (June 2021)

• Record Type: Journal Article
• Authors: Sattar, Yasar; Majmundar, Monil; Almas, Talal; Song, David; Ullah, Waqas; Pacha, Homam Moussa; Zghouzi, Mohamed; Elgendy, Islam Y.; Murtaza, Fatir; Alraies, M. Chadi
• Is Part Of: Annals of medicine and surgery. Volume 66(2021)
• Publication Date: 2021-06
• Subjects: Vena cava occlusion -- Heart failure with reduced ejection fraction -- Preload reduction; Surgery -- Periodicals; Medicine -- Periodicals; General Surgery -- Periodicals; Education, Medical -- Periodicals; Periodicals; 617
• DOI: 10.1016/j.amsu.2021.102387
• Languages: English
• ISSNs: 2049-0801

Abstract

Abstract: Background: Patients with acute decompensated heart failure are prone to recurrent exacerbation leading to poor quality of life when they do not respond to an optimal medical regimen. Due to the lack of linear positive inotropy response to increasing preload in heart failure patients, increasing preload is associated with poor outcomes. Partial occlusion of either IVC or SVC is a proposed novel treatment that can improve cardiac function or quality of life by altering preload/pressure in heart failure (HF) patients unresponsive to diuretics. Methods: PubMed, Ovid (MEDLINE), and Cochrane database we searched using the MeSH terms including "Superior vena cava occlusion, " "Inferior vena cava occlusion, " "Heart failure exacerbation." The inclusion criteria included studies that enrolled patients > 18 years with diagnosed NYHA II-IV HF with reduced ejection fraction (HFrEF) on optimal medical treatment (OMT). Results: The analysis involved two studies with 14 patients; the mean age was 64.4 ± 10 and 100% males. The difference in the mean pulmonary pressures between pre-and-post VCO devices were 1.56 (95% CI 0.66–2.46, p-value = 0.006). There was no heterogeneity among the study of mean pulmonary pressures. With the use of VC occlusion devices, the mean difference in pulmonary artery systolic pressure decreased by 1.70 (95% CI 0.68–2.71, p-value = 0.001) (Fig. 1B). The heterogeneity of mean pressure was minimal 14%. Conclusion: In conclusion, VCO can help decrease pulmonary pressure that can indirectly prevent heart failure exacerbations and possibly hospitalization in this cohort of patients. Highlights: Patients with acute decompensated heart failure are prone to recurrent exacerbation when they do not respond to an optimal medical regimen. Partial occlusion of either IVC or SVC is a proposed novel treatment that can improve cardiac function or quality of life by altering preload/pressure in heart failure (HF) patients. The choice of vena cava for device implantation is also essential. However, it is not well discussed in the literature. This meta-analysis aims to bridge the gap in literature that precludes the uptake of partial VCO as a routine treatment modality for refractory heart failure.